Abstract
The glutamatergic cortico-striatal and subthalamo-entopeduncular pathways are both overactive in parkinsonism. Previous behavioural investigations have shown that intra-entopeduncular injection of either NMDA-site or glycine-site antagonists results in alleviation of parkinsonian symptoms, although injection of the former is associated with the appearance of anaesthetic-like side effects. These behavioural differences may be mediated by action on different NMDA receptor subtypes. Recent neurochemical and molecular pharmacological studies have indicated the existence of NMDA receptor subtypes which display differential modulation by glycine. In the present study, three potential modes of NMDA antagonism were differentiated in vitro by effects on [3H]-glycine binding to striatal sections. Specific [3H]-glycine binding was totally displaced by the glycine partial agonist (R)-HA-966; the NMDA-site antagonistd-CPP had no effect; and the NMDA-site antagonistd-AP5 displaced [3H]-glycine binding in a subpopulation of glycine sites. The anti-parkinsonian effects of (R)-HA-966,d-CPP andd-AP5 were assessed by intra-striatal injection in reserpine-treated rats and 6-OHDA-lesioned rats. Injection of (R)-HA-966 andd-CPP resulted in alleviation of parkinsonian akinesia, although the latter elicited anaesthetic-like side effects;d-AP5 was ineffective as an anti-parkinsonian agent. (R)-HA-966 was also effective as an anti-parkinsonian agent when administered systemically in the reserpine-treated rat. These data suggest that different classes of NMDA antagonist mediate different behavioural responses within the parkinsonian striatum. The behavioural response produced may depend on the exact nature of the conformational change induced by the antagonist and the location of the subtype most sensitive to that class of compound. Selection of a specific mode of NMDA receptor antagonism or targeting of striatal NMDA receptor subtypes may form the basis of a novel therapeutic approach to Parkinson's disease.
Similar content being viewed by others
References
Beaton JA, Stemsrud K, Monaghan DT (1992) Identification of a novelN-methyl-d-aspartate receptor population in the rat medial thalamus. J Neurochem 59:754–757
Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Move Disord 8[2]:133–138
Buller AL, Morrisett RA, Monaghan DT (1993) The NR2 subunit contributes to the pharmacological diversity of native NMDA receptors. Soc Neurosci Abstr 19(2):1356, 557.10
Cai N, Kiss B, Erdö SL (1991) Heterogeneity ofN-methyl-d-aspartate receptors regulating the release of dopamine and acetylcholine from striatal slices. J Neurochem 57:2148–2151
Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221–226
Crossman AR (1989) Mini review: neural mechanisms in disorders of movement. Comp Biochem Physiol 93A [1]:141–149
Danysz W, Fadda E, Wroblewski JT, Costa E (1989) Different modes of action of 3-amino-1-hydroxy-2-pyrrolidone (HA-966) and 7-chlorokynurenic acid in the modulation ofN-methyl-d-aspartate-sensitive glutamate receptors. Mol Pharmacol 36:912–916
Dunn RW, Flanagan DM, Martin LL, Kerman LL, Woods AT, Camacho F, Wilmot CA, Cornfeldt ML, Effland RC, Wood PL, Corbett R (1992) Stereoselective (R)-(+) enantiomer of HA-966 displays anxiolytic effects in rodents. Eur J Pharmacol 214:207–214
Foster AC, Kemp JA (1989) HA-966 antagonisesN-methyl-d-aspartate receptors through a selective interaction with the glycine modulatory site. J Neurosci 9(6):2191–2196
Graham WC, Robertson RG, Sambrook MA, Crossman AR (1990) Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 47:91–97
Greenamyre JT (1993) Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neurotransmi 91:255–269
Grimwood S, Wilde GJC, Foster AC (1993) Interactions between the glutamate and glycine recognition sites of theN-methyl-d-aspartate receptor from rat brain, as revealed from radioligand binding studies. J Neurochem 60:1729–1738
Harris NC, Davies J (1992) Cortically evoked excitatory synaptic transmission in the cat nucleus is antagonised byd-AP5 but not byd-AP7. Brain Res 594:176–180
Hood WF, Compton RP, Monahan JB (1990)N-methyl-d-aspartate recognition site ligands modulate activity at the coupled glycine recognition site. J Neurochem 54:1040–1046
Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured brain neurons. Nature 325:529–531
Kaplita PV, Ferkany JW (1990) Evidence for direct interactions between the NMDA and glycine recognition sites in brain. Eur J Pharmacol 188:175–179
Kessler M, Baudry M, Terramani T, Lynch G (1987) Complex interactions between a glycine binding site and NMDA receptors. Soc Neurosci Abstr 13:760
Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated withN-methyl-d-aspartic acid receptors: characterisation and identification of a new class of antagonists. J Neurochem 52:1319–1328
Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA receptors expressed inXenopus oocytes. Science 241:835–836
Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions ofl-Dopa in monoamine-depleted rats. Ann Neurol 28:539–546
Klockgether T, Turski L (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 34:585–593
Klockgether T, Turski L, Honoré T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 30:717–723
Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina M (1992) Molecular diversity of the NMDA receptor channel. Nature 358:36–41
McDonald JW, Uckele J, Silverstein FS, Johnston MV (1989) HA-966 (1-hydroxy-3-aminopyrrolidone-2) selectively reducesN-methyl-d-aspartate (NMDA)-mediated brain damage. Neurosci Let 104:167–170
McDonald JW, Penney JB, Johnston MV, Young AB (1990). Characterization and regional distribution of strychnine-insensitive [3H] glycine binding sites in rat brain by quantitative receptor autoradiography. Neuroscience 35 [3]:653–668
McMillen BA, Williams HL, Lehmann H, Shepard PD (1992) On central muscle relaxants, strychnine-insensitive glycine receptors and two old drugs: zoxazolamine and HA-966. J Neural Transm 89:11–25
Meguro H, Mori H, Araki K, Kushiya E, Kutsuwada T, Yamazaki M, Kumanishi T, Arakawa M, Sakimura K, Mishina M (1992) Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357:70–74
Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci 32:213–226
Monaghan DT (1991) Differential stimulation of [3H]MK-801 binding to subpopulations of NMDA receptors. Neurosci Lett 122:21–24
Monaghan DT, Beaton JA (1991) Quinolinate differentiates between forebrain and cerebellar NMDA receptors. Eur J Pharmacol 194:123–125
Monaghan DT, Cotman CW (1985) Distribution ofN-methyl-d-aspartate-sensitive L-[3H]-glutamate-binding sites in rat brain. J Neurosci 5:2909–2919
Monaghan DT, Clark HC, Schneider BE (1993) Distributions of NMDA receptor subtypes correspond to specific receptor subunits. Soc Neurosci Abstr 19[2]:1356,557.9
Monahan JB, Corpus VM, Hood WF, Thomas JW, Compton RP (1989) Characterization of a [3H]glycine recognition site as a modulatory site of theN-methyl-d-aspartate receptor complex. J Neurochem 53(2):370–375
Monahan JB, Biesterfeldt JP, Hood WF, Compton RP, Cordi AA, Vazquez MI, Lanthorn TH, Wood PL (1990) Differential modulation of the associated glycine recognition site by competitiveN-methyl-d-aspartate receptor antagonists. Mol Pharmacol 37:780–784
Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354:31–37
Morris RGM, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by anN-methyl-d-aspartate receptor antagonist, AP5. Nature 319:774–776
O'Shea RD, Manallack DT, Conway EL, Mercer LD, Beart PM (1991) Evidence for heterogeneous glycine domains but conserved multiple states of the excitatory amino acid recognition site of the NMDA receptor: regional binding studies with [3H]glycine and [3H]L-glutamate. Exp Brain Res 86:652–662
Overton P, Clark D (1992) Electrophysiological evidence that intrastriatally administeredN-methyl-d-aspartate augments striatal dopamine tone in the rat. J Neural Transm 4:1–14
Perkins MN, Stone TW (1983) Quinolinic acid: regional variations in neuronal sensitivity. Brain Res 259:172–176
Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic Press
Pullan LM, Britt M, Chapdeline MJ, Keith RA, LaMonte D, Mangano TJ, Patel J, Powel RJ, Stumpo RJ, Warwick PJ, Zinkand WC, Salama AI (1990) Stereoselectivity for the (R)-enantiomer of HA-966 (1-hydroxy-3-aminopyrrolidinone-2) at the glycine site of theN-methyl-d-aspartate receptor complex. J Neurochem 55:1346–1351
Pullan LM, Verticelli AM, Paschetto KA (1991) Agonist-like character of the (R)-enantiomer of 1-hydroxy-3-amino-pyrroli-2-one (HA-966). Eur J Pharmacol 208:25–29
Ransom RW, Deschenes NL (1989) Glycine modulation of NMDA-evoked release of [3H]-acetylcholine and [3H]-dopamine from rat striatal slices. Neurosci Lett 96:323–328
Reynolds IJ, Murphy SN, Miller RJ (1987)3H-Labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci 84:7744–7748
Sekiguchi M, Okamoto K, Sakai Y (1990) Glycine-insensitive NMDA-sensitive receptor expressed inXenopus oocytes by guinea pig cerebellar mRNA. J. Neurosci 10[7]:2148–2155
Singh L, Donald AE, Foster AC, Hutson PH, Iversen LL, Iversen SD, Kemp JA, Leeson PD, Marshall GR, Oles RJ, Priestley T, Thorn L, Tricklebank MD, Vass CA, Williams BJ (1990) Enantiomers of HA-966 (3-amino-hydropyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selectiveN-methyl-d-aspartate receptor antagonist, but (—)-HA-966 is a potent γ-butyrolactone-like sedative. Proc Natl Acad Sci 87:347–351
Sircar R, Zukin SR (1991) Kinetic mechanisms of glycine requirement forN-methyl-d-aspartate channel activation. Brain Research 556:280–284
Svensson A, Carlsson ML (1992) Injection of the competitive NMDA receptor antagonist AP5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation. Neuropharmacology 31[5]:513–518
Thomson AM (1990) Glycine is a coagonist at the NMDA receptor/channel complex. Progress in Neurobiol 35:53–74
Vartanian MG, Taylor CP (1991) Different stereoselectivity of the enantiomers of HA-966 (3-amino-1-hydroxy-2-pyrrolidinone) for neuroprotective and anticonvulsant actions in vivo. Neurosci Lett 133:109–112
Williams TL, Stone TW, Burton NR, Smith DAS (1988). Kynurenic acid and AP5 distinguish between NMDA receptor agonists. Exp Neurol 102:366–367
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carroll, C.B., Holloway, V., Brotchie, J.M. et al. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for treatment of parkinsonian symptoms. Psychopharmacology 119, 55–65 (1995). https://doi.org/10.1007/BF02246054
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246054